U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439653) titled 'A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma' on Feb. 10.
Brief Summary: A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Study Start Date: Jan. 30
Study Type: INTERVENTIONAL
Condition:
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Intervention:
DRUG: TORL-5-700
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
DRUG: TORL-5-700 at MTD/RP2D
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Admini...